Anti-West Nile Virus (Clone: WNV-86)-Purified No Carrier Protein
Produktgrößen
250µg
£583,00
12-8272-250UG
1 mg
£812,00
12-8272-1MG
Über dieses Produkt
- SKU:
- 12-8272
- translate.label.attr.clone:
- WNV-86
- Klonalität:
- Monoclonal
- Weitere Details:
- Specificity: WNV-86 targets E domain II; preferentially recognizing mature virions lacking prM. Antigen Distribution: E protein is preferentially displayed on mature virions. Background: West Nile Virus (WNV) is a mosquito-borne; enveloped; positive-stranded RNA flavivirus1. E protein is the main target of flavivirus neutralizing antibodies. E consists of three structural domains (DI; DII; DIII). WNV-86 was generated from peripheral blood mononuclear cells from donors with a history of symptomatic WNV infection1. B cells were transformed with Epstein Barr virus and screened for binding to recombinant soluble WNV E protein. Ten hybridomas were recovered; including WNV-86; which strongly neutralized WNV reporter virus particles (RVP) and completely inhibited fully infectious WNV. WNV-86 is one of the most potently neutralizing flavivirus-specific antibodies ever isolated; neutralizing 50% of virus infectivity at an IC50 of 2 ng/mL. WNV-86 also inhibited infection as a Fab fragment. WNV-86 did not neutralize Dengue or Zika virus. Neutralization escape mutations were generated in Vero cells under WNV-86 selection pressure1. Two amino acid residues in E DII; T64 and T208; individually reduced sensitivity to neutralization and when combined abrogated neutralization. Additionally; a cluster of six mutations in DII that are bound by T64 and T208 reduced neutralization sensitivity by >4 fold; suggesting a binding footprint that partially overlaps with the E binding site of prM. Indeed; virion maturation state affected neutralization. The IC50 of WNV-86 was 4-fold lower against prM- RVPs relative to prM+ RVPs. WNV-86 completely protected mice from mortality when given a single dose post-inoculation1. A LALA variant of WNV-86 that is incapable of engaging Fc receptor gave significant but reduced protection. Both wildtype and LALA WNV-86 reduced viral burden in the spinal cord and brain of infected animals. WNV-86 blocked infection in pre- and post-attachment assays1. WNV-86 is of the IgG1 isotype.
- Isotyp:
- Human IgG1
- Aufreinigung:
- Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are pu
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- This antibody may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at
- Hersteller:
- Abeomics
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules
- Datenblatt des Herstellers:download_pdf.php